The Journal of Contemporary Dental Practice

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Related articles

VOLUME 19 , ISSUE 10 ( 2018 ) > List of Articles

ORIGINAL RESEARCH

Evaluation of Serum Desmoglein 1 and Desmoglein 3 in Oral Erosive Lichen Planus before and after Topical Application of Tacrolimus

Islam Saad, Suzan Salem

Keywords : anti-Dsg1, anti-Dsg3, Oral erosive lichen planus, Topical tacrolimus.

Citation Information : Saad I, Salem S. Evaluation of Serum Desmoglein 1 and Desmoglein 3 in Oral Erosive Lichen Planus before and after Topical Application of Tacrolimus. J Contemp Dent Pract 2018; 19 (10):1204-1213.

DOI: 10.5005/jp-journals-10024-2406

License: CC BY-NC 3.0

Published Online: 00-10-2018

Copyright Statement:  Copyright © 2018; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

Aim: The current study will attempt to throw light on the role of desmoglein 1 and desmoglein 3 in the pathogenesis of erosive lichen planus and their response to topical application of tacrolimus. Materials and methods: Twenty patients with erosive oral lichen planus received tacrolimus ointment three times daily for eight weeks. Assessments using the clinical score and a visual analog scale were recorded at each visit. Serum concentrations of circulating autoantibodies to desmoglein 1 and desmoglein 3 will be determined by enzyme-linked immunosorbent assay (ELISA) at baseline, four weeks and eight weeks after treatment. Statistical software SPSS v.17.0 was used for statistical analysis. Results: All patients showed significant improvement in all outcomes within the follow-up periods when compared with the baseline (p < 0.05). The mean value of the visual analog scale were 8.30 ± 1.49, 4.15 ± 1.14, 2.10 ± 0.91, 0.90 ± 0.79, and 0.0 ± 0.0 starting from baseline to the end of follow up period. The mean value of the clinical score were 4.7 ± 0.48, 2.9 ± 1.29, 1.8 ± 1.32, 1.31 ± 0.69, and 0.69 ± 0.09 starting from baseline to the end of follow-up period. There was a significant decrease in the levels of anti-Dsg1 and anti-Dsg3, during the follow-up period (p ≤ 0.05). Conclusion: The concluded data suggest that antibodies against desmoglein 1 and desmoglein 3 seem to play a key role in the pathogenesis of oral lichen planus. Also, there is a significant decrease in the level of anti-Dsg1 and anti-Dsg3 autoantibodies with topical tacrolimus 0.1% ointment. Clinical significance: Monitoring the serum level of antibodies against keratinocyte cadherins Dsg 1 and Dsg 3 can be used to evaluate the effect of topical application of tacrolimus on Erosive Oral lichen planus.


PDF Share
  1. Eisen D. The evaluation of cutaneous, genital, scalp, nail, esophageal, and ocular involvement in patients with oral lichen planus. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1999;88:431-436.
  2. Sugerman PB, Savage NW, Walsh LJ, Zhao ZZ, Zhou XJ, Khan A, et al. The pathogenesis of oral lichen planus. Crit Rev Oral Biol Med 2002;13(4):350-365.
  3. Epstein JB, Wan LS, Zhang L. Oral lichen planus: Progress in understanding its malignant potential and the implication for clinical management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2003;96:32-37.
  4. Cawson RA, Odell EW. Diseases of the oral mucosa: noninfective stomatitis, lichen planus. Cawsons essentials of oral pathology and oral medicine. 8th ed. Churchill Livingstone, 2008. 225-227.
  5. Andreasen JO. Oral lichen planus. 1. A clinical evaluation of 115 cases. Oral Surg Oral Med Oral Pathol 1968; 25: 31-42. Coated from Al Robaee AA, Al Zolibani AA. Oral lichen planus and hepatitis C virus: is there real association? Acta Dermatoven APA 2000;15:14-19.
  6. Sugerman PB, Savage NW, Walsh LJ, Zhao ZZ, Zhou XJ, Khan A, et al. The pathogenesis of oral lichen planus. Crit Rev Oral Biol Med 2002;13:350-365.
  7. Scardina GA, Ruggieri A, Messina P. Correlation of “in vivio” microcirculation and degeneration of the basal cells of the epithelium in lingual lichen planus. Indian J Dent Res 2009;20:407-411.
  8. Schiodt M, Holmstrup P, Dabelsteen E, Ullman S. Deposits of immunoglobulins, complement, and fibrinogen in oral lupus erythematosus, lichen planus, and leukoplakia. Oral Surg Oral Med Oral Pathol. 1981;51:603-608.
  9. Sistig S, Vucicevic-Boras V, Lukac J, Kusic Z. Salivary IgA and IgG subclasses in oral mucosal diseases. Oral Dis. 2002;8:282-286.
  10. Ingafos M, Lodi G, Olsca 1, Porter SR. Oral lichen planus is not associated with IgG circulating antibodies to epithelial antigens. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997;84:175-178
  11. Sistig S, Lukac J, Vucicevic-Boras V, Malenica B. DSG 3 and DSG 1-ELISA as a specific diagnostic tool in oral bullous diseases. Eur J Med Res. 2002;7:181-182.
  12. Nousari HC, Anhalt GJ. Autoimmune bullous diseases. Curr Probl Dermatol. 2000;28:17-24.
  13. Amagai M. Desmoglein as a target in autoimmunity and infection. J Am Acad Dermatol. 2003;48:244-252.
  14. D'Agosto G, Latini A, Carducci M, Mastroianni A, Vento A, Fei PC. Evaluation of recombinant antigen-based assays for diagnosis of bullous autoimmune diseases. Clin Diagn Lab Immunol. 2004;11:762-765.
  15. Lodi G, Scully C, Carrozzo M, Griffiths M, Sugerman PB, Thongprasom K. Current controversies in oral lichen planus: Report of an international consensus meeting. Part 2. Clinical management and malignant transformation. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2005;100:40-51.
  16. Cribier B, Frances C, Chosidow O. Treatment of lichen planus. An evidence based medicine analysis of efficacy. Arch Dermatol 1998;134:1521-1530.
  17. Al-Hashimi I, Schifter M, Lockhart PB, et al. Oral lichen planus and oral lichenoid lesions: diagnostic and therapeutic consideration. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007; 103(Suppl.): S25.el-12.
  18. Petruzzi M, De Benedittis M, Grassi R, Cassano N, Vena G, Serpico R. Oral lichen planus: A preliminary clinical study on treatment with tazarotene. Oral Dis 2002; 8(6): 291- 295.
  19. Naylor GD. Treating erosive lichen planus with griseofulvin: a report of four cases. Quintessence Int 1990; 21: 943-7.
  20. Lehtinen R, Happonen RP, Kusilehto A, Jansen C. A clinical trial of PUVA treatment in oral lichen planus. Proc Finn Dent Soc 1989; 85: 229-233
  21. Ismail SB, Kumar SKS, Zain RB. Oral lichen planus and lichenoid reaction: Etiopathogenesis, diagnosis, management and malignant transformation. J Oral Science 2007; 49:89
  22. Eisen D, Carrozzo M, Bagan Sebastian JV, Thongprasom K. Number V Oral lichen planus: clinical features and management. Oral Dis 2005; 11: 338-349.
  23. Kelly PA, Burckart GJ, Venkataramanan R. Tacrolimus: a new immunosuppressive agent. Am J Health Syst Pharm 1995;52:1521-1535.
  24. Schreiber SL and Crabtree GR. The mechanism of action of cyclosporin A and FK506. Immunol Today 1992;13:136-142.
  25. Ruzicka T, Assmann T, Homey B. Tacrolimus: the drug for the turn of the millennium?. Arch Dermatol 1999;135:574- 580.
  26. The European FK 506 Multicentre Psoriasis Study Group. Systemic tacrolimus (FK 506) is effective for the treatment of psoriasis in a double-blind, placebo-controlled study. Arch Dermatol 1996;132:419-423.
  27. Sakane T, Mochizuki M, Inaba G, Masuda K. [A phase II study of FK506 (tacrolimus) on refractory uveitis associated with Behçet's disease and allied conditions]. Ryumachi 1995;35:802-813.
  28. Abu-Elmagd K, Jegasothy BV, Ackerman CD, Thomson AW, Rilo H, Nikolaidis N, et al. Efficacy of FK 506 in the treatment of recalcitrant pyoderma gangrenosum. Transplant Proc 1991;23:3328-3329.
  29. McCauley J, Shapiro R, Scantlebury V, Gilboa N, Jordan M, Jensen C, et al. FK 506 in the management of transplantrelated nephrotic syndrome and steroid-resistant nephrotic syndrome. Transplant Proc 1991;23:3354-3356.
  30. Nghiem P, Pearson G, Langley RG. Tacrolimus and pimecrolimus: from clever prokaryotes to inhibiting calcineurin and treating atopic dermatitis. J Am Acad Dermatol 2002;46:228-241
  31. Lauerma AI, Maibach HI, Granlund H, Erkko P, Kartamaa M, Stubb S. Inhibition of contact allergy reactions by topical Fk506. Lancet 1992;340:556.
  32. Goldman D. Tacrolimus ointment for the treatment of steroid-induced rosacea: a preliminary report. J Am Acad Dermatol 2001;44:995-998.
  33. Suresh L, Martinez Calixto LE, Radfar L. Successful treatment of mucous membrane pemphigoid with tacrolimus. Spec Care Dentist 2006;26:66-70.
  34. Hodgson TA, Malik F, Hegarty AM, Porter SR. Topical tacrolimus: a novel therapeutic intervention for recalcitrant labial pemphigus vulgaris. Eur J Dermatol 2003;13:142- 144.
  35. Casson DH, Eltumi M, Tomlin S, Walker-Smith JA, Murch SH. Topical tacrolimus may be effective in the treatment of oral and perineal Crohn's disease. Gut 2000;47:436-440.
  36. US Food and Drug Administration. FDA Public Health Advisory: Elidel (pimecrolimus) cream and Protopic (tacrolimus) ointment. Available at: http://www.fda.gov/ cder/drug/advisory/elidel_protopic.htm (accessed March 10,2005).
  37. Berger TG, Duvic M, Van Voorhees AS, Van Beek MJ, Frieden IJ, American Academy of Dermatology Association Task Force. The use of topical calcineurin inhibitors in dermatology: safety concerns. Report of the American Academy of Dermatology Association Task Force. J Am Acad Dermatol 2006; 54: 818–823.
  38. Van Der Meij EH, Van Der Waal I. Lack of clinicopathologic correlation in the diagnosis of oral lichen planus based on the presently available diagnostic criteria and suggestions for modifications. J Oral Pathol Med 2003;32:507-512.
  39. Shankargouda Patil, Roopa S. Rao, D. S. Sanketh, Sachin C. Sarode, Gargi S. Sarode, “A universal diagnostic criteria for oral lichen planus: An exigency!,” Int J Contemp Dent Med Rev, vol. 2014, Article ID 041214, 2014.
  40. Canto AM, Müller H, Freitas, RR, da Silva Santos PS. Oral lichen planus (OLP): Clinical and complementary diagnosis. An Bras Dermatol. 2010;85:669-675.
  41. Merva Soluk-Tekke IN, John M. Wrigh. The World Health Organization Classification of Odontogenic Lesions: A Summary of the Changes of the 2017 (4th) Edition. Turkish journal of pathology 2018;34:1:1-18.
  42. Huskisson EC, Jones J, Scott PJ. Application of visualanalogue scales to the measurement of functional capacity. Rheumatol Rehabil. 1976;15:185-187.
  43. Thongprasom K, Luangjarmekorn L, Sererat T, Taweesap W. Relative efficacy of fluocinolone acetonide compared with triamcinolone acetonide in treatment of oral lichen planus. J Oral Pathol Med 1992;21: 456-458.
  44. Thongprasom K, Luengvisut P, Wongwatanakij A, Boonjatturus C. Clinical evaluation in treatment of oral lichen planus with topical fluocinolone acetonide: A 2-year followup. J Oral Pathol Med 2003;32:315-322.
  45. Lukac J, Malenica B. Serum Autoantibodies to Desmogleins 1 and 3 in Patients with Oral Lichen Planus. Croat Med J 2006;47:53-58.
  46. Mollaoglu N. Oral lichen planus: a review. Br J Oral Maxillofac Surg 2000;38:370-377.
  47. Eisen D. The clinical features, malignant potential, and systemic associations of oral lichen planus: a study of 723 patients. J Am Acad Dermatol 2002;46:207-214.
  48. Małgorzata Radwan-Oczko. Topical application of drugs used in treatment of oral lichen planus lesions. Adv Clin Exp Med. 2013;22:893–898.
  49. Shailaja G, Kumar JV, Baghirath PV, Kumar U, Ashalata G, Krishna AB. Estimation of malignant transformation rate in cases of oral epithelial dysplasia and lichen planus using immunohistochemical expression of Ki-67, p53, BCL-2, and BAX markers. Dental Res J. 2015;12:235-242.
  50. Chainani-Wu N, Lozada-Nur F, Terrault N. Hepatitis C virus and lichen planus: a review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2004;98:171-183.
  51. Kattalee K, Efficacy of centella asiatica in ora base in the treatment of oral lichen planus and oral lichenoid lesions Oral Med Oral Pathol 2005;2:8-10.
  52. Piboonniyom SO, Treister N, Pitiphat W, Woo SB. Scoring system for monitoring oral lichenoid lesions: a preliminary study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2005;99:696-703.
  53. Rozycki TW, Rogers RS III, Pittelkow MR, McEvoy MT, el-Azhary RA, Bruce AJ, et al. Topical tacrolimus in the treatment of symptomatic oral lichen planus: a series of 13 patients. J Am Acad Dermatol 2002;46:27-34.
  54. Kaliakatsou F, Hodgson TA, Lewsey JD, Hegarty AM, Murphy AG, Porter SR. Management of recalcitrant ulcerative oral lichen planus with topical tacrolimus. J Am Acad Dermatol 2002;46:35-41.
  55. Morrison L, Kratochvil FJ III, Gorman A. An open trial of topical tacrolimus for erosive oral lichen planus. J Am Acad Dermatol 2002;47:617-620.
  56. Lozada-Nur FI and Sroussi HY. Tacrolimus powder in Orabase 0.1% for the treatment of oral lichen planus and oral lichenoid lesions: an open clinical trial. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006;102:744- 749.
  57. Laeijendecker R, Tank B, Dekker SK, Neumann HA. A comparison of treatment of oral lichen planus with topical tacrolimus and triamcinolone acetonide ointment. Acta Derm Venereol 2006;86:227-229.
  58. Radfar L, Wild RC, Suresh L. A comparative treatment study of topical tacrolimus and clobetasol in oral lichen planus. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008;105:187-193.
  59. Donetti E, Bedoni M, Boschini E, Dellavia C, Barajon I, Gagliano N. Desmocollin 1 and desmoglein 1 expression in human epidermis and keratinizing oral mucosa: a comparative immunohistochemical and molecular study. Arch Dermatol Res 2005;297:31-8.
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.